Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback